# The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old

> **NCT05089123** · PHASE3 · COMPLETED · sponsor: **St. Petersburg Research Institute of Vaccines and Sera** · enrollment: 320 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Flu-M [Inactivated split influenza vaccine]
- **BIOLOGICAL:** Inactivated Split Influenza Vaccine

## Key facts

- **NCT ID:** NCT05089123
- **Lead sponsor:** St. Petersburg Research Institute of Vaccines and Sera
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-03
- **Primary completion:** 2020-05-28
- **Final completion:** 2020-08-24
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2022-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05089123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05089123, "The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05089123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*